News
Tata Capital Healthcare Fund II invests up to $20 M in Orbicular Pharmaceutical Technologies
IMT News Desk
4 months ago
Tata Capital Healthcare Fund II invests up to $20 M in Orbicular Pharmaceutical Technologies
IMT News Desk
4 months ago
Investment towards accelerating the development of the product pipeline
Tata Capital Healthcare Fund II (TCHF II), the healthcare-focussed private equity fund of Tata Capital, has invested an amount of $ c.20 million in Orbicular Pharmaceutical Technologies for an undisclosed equity stake. Orbicular, a Hyderabad-based speciality pharmaceutical company, excelling in developing complex generics for global pharmaceutical markets will utilise the capital to accelerate the development of the product pipeline.
Orbicular has developed a robust pipeline of niche products in the speciality generics space positioning them as an ideal partner for global generic players targeting regulated markets.
Visalakshi Chandramouli, Managing Partner, Tata Capital Healthcare Fund said, “We are thrilled to partner with Orbicular which is at the forefront of R&D leadership in the field of complex generics. Under the able leadership of Dr MS Mohan, Orbicular has developed a strong product pipeline for the regulated markets. We are proud to support the dynamic team at Orbicular and be a part of their growth story. This investment reinforces our fund’s core philosophy of identifying the big shifts in the industry and being a 'capital plus partner to our companies."
Dr MS Mohan, Managing Director, Orbicular said, “Today is a transformative milestone in our journey of starting as a bootstrapped company to successfully being backed by Tata Capital Healthcare Fund. Having positioned Orbicular as a differentiated speciality pharmaceutical company in the complex generics space, the investment will further strengthen our global partnerships. I am proud of our team, and its achievements, and together, we will continue to drive differentiation, pursue advanced healthcare solutions, and make a positive impact on the lives of millions across the globe.”
Dr Hiren Patel, CEO, Orbicular said “The new partnership with Tata Capital Healthcare Fund is a testament to our capabilities and will enable us to accelerate our R&D efforts, expand our portfolio and strengthen our global partnerships.”
Ambit acted as the exclusive financial advisor to Orbicular and its shareholders on this transaction. Vikas Khattar - MD, Co- Head Investment Banking and Head - ECM at Ambit and Ritesh Desai, Executive Director – Pharma & Healthcare Investment Banking, have been key to this partnership.
Recommended
WHO approves first mpox diagnostic test by Abbott Molecular
October 5, 2024
KIMS Hospitals signs MoU with Intuitive
October 4, 2024